BioLineRx Ltd. Reports Q1 2024 Financial Results
Ticker: BLRX · Form: 6-K · Filed: May 28, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, quarterly-report
TL;DR
BioLineRx dropped Q1 2024 earnings on 5/28 - check financials.
AI Summary
BioLineRx Ltd. announced its financial results for the three months ended March 31, 2024, on May 28, 2024. The company also published its unaudited interim consolidated financial statements and operating and financial review as of that date.
Why It Matters
This filing provides investors with the latest financial performance and operational update for BioLineRx Ltd., crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no new material events or significant changes indicated.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- May 28, 2024 (date) — Date of press release and filing
- March 31, 2024 (date) — Reporting period end date
FAQ
What is the filing type and purpose?
This is a Form 6-K, a Report of Foreign Private Issuer, used by BioLineRx Ltd. to announce its financial results for the three months ended March 31, 2024.
When were the financial results announced?
The financial results were announced on May 28, 2024.
What period do the financial statements cover?
The unaudited interim consolidated financial statements cover the three months ended March 31, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or 40-F?
BioLineRx Ltd. files annual reports under Form 20-F.
Filing Stats: 281 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-05-28 07:11:36
Filing Documents
- zk2431511.htm (6-K) — 9KB
- exhibit_1.htm (EX-99.1) — 295KB
- exhibit_2.htm (EX-99.2) — 345KB
- exhibit_3.htm (EX-99.3) — 187KB
- image00001.jpg (GRAPHIC) — 231KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001178913-24-001842.txt ( ) — 1160KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On May 28, 2024, the Registrant issued a press release announcing its financial results for the three months ended March 31, 2024. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of March 31, 2024 and for the three months then ended. Attached hereto are the following exhibits: Exhibit 1: Registrant's press release dated May 28, 2024; Exhibit 2: Registrant's condensed consolidated interim financial statements as of March 31, 2024 and for the three months then ended; and Exhibit 3: Registrant's operating and financial review as of March 31, 2024 and for the three months then ended. This Form 6-K, the text under the heading "Financial Results for the Quarter Ended March 31, 2024" in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: May 28, 2024